Recording Seizure Signals Under the Scalp in Adults With Drug-Resistant Epilepsy
Compares scalp-layer brain recordings with standard monitoring in adults with drug-resistant epilepsy.
Plain-language title generated from the registry record
Registry title: Translational Recording and Characterization of Epilepsy Signals Using Subgaleal EEG During Standard-of-care SEEG Monitoring
Key facts
- Where
- Minneapolis, United StatesSee the site
- Phase
- Early phase 1
Where in United States
- University of MinnisotaMinneapolis, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Adraxe Corp.
- Trial code
- NCT07821697
- Record updated
- 16 September 2026
- Original description
TRACE is a record-only study evaluating subgaleal EEG (sgEEG) recorded concurrently with standard-of-care stereoelectroencephalography (SEEG) in adults with drug-resistant epilepsy undergoing inpatient epilepsy monitoring. The study will assess the ability of sgEEG to detect seizures and characterize seizure timing, signal quality and stability, and lateralization compared with SEEG.Read full original descriptionShow less
Translational Recording and Characterization of Epilepsy Signals Using Subgaleal EEG During Standard-of-care SEEG Monitoring
TRACE is a record-only study evaluating subgaleal EEG (sgEEG) recorded concurrently with standard-of-care stereoelectroencephalography (SEEG) in adults with drug-resistant epilepsy undergoing inpatient epilepsy monitoring. The study will assess the ability of sgEEG to detect seizures and characterize seizure timing, signal quality and stability, and lateralization compared with SEEG.
Inclusion: Adults aged 18 years or older; Diagnosis of drug-resistant epilepsy; Scheduled to undergo clinically indicated inpatient standard-of-care stereoelectroencephalography (SEEG) monitoring; Able and willing to provide written informed consent; In the investigator's judgment, able to comply with study procedures.
Exclusion: Any medical, neurological, psychiatric, or social condition that, in the investigator's judgment, would make participation unsafe or interfere with study procedures or data interpretation; Active infection, skin condition, or other finding at the planned subgaleal electrode placement site that could increase procedural risk; Known bleeding disorder, clinically significant coagulopathy, or use of anticoagulant/antiplatelet therapy that cannot be managed per institutional requirements for the planned procedure; Pregnancy or breastfeeding; Participation in another investigational study that, in the investigator's judgment, could interfere with TRACE procedures or outcomes.